DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma today announced full results from its phase-IIIb DIAMOND trial showing that Veltassa® allowed patients to achieve long-term potassium control, reduced the risk of recurrent hyperkalemia and prolonged optimized and guideline recommended renin-angiotensin aldosterone system inhibitor (RAASi) therapy. The findings were presented at the 71st Annual Scientific Session & Expo of the American College of Cardiology (ACC) in Washington D.C., U.S.
DIAMOND is the largest interventional study to date for potassium binders investigating the benefits of potassium control in more than 1,000 patients. The trial met its primary and all five key secondary endpoints.
- Treatment with Veltassa® lowered the risk of hyperkalemia events by 37%
- Veltassa® statistically prevented hyperkalemia with more patients being able to maintain Mineralocorticoid Receptor Antagonists (MRA) therapy at target doses compared to placebo
- Patients with chronic kidney disease observed a greater benefit with Veltassa®
- Veltassa® was generally well tolerated and without unexpected safety findings
“We are very encouraged by the full results of the DIAMOND trial which are a milestone for patients suffering from heart failure,” said Dr. Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma. “Data from this trial demonstrated that Veltassa® controlled serum potassium and reduced the risk of recurrent hyperkalemia, while allowing more patients to be treated with guideline recommended, life-saving RAASi therapy.”
“These results are further evidence for the use of potassium binders to optimize heart failure medical therapy,” commented Prof. Javed Butler, Principal Investigator for the DIAMOND study. “RAASi offers significant survival benefits for these patients, but due to risk of hyperkalemia these therapies are unfortunately underutilized in practice. For cases where hyperkalemia is the dominant reason for not giving guideline-directed RAASi therapy, Veltassa® can be an enablement strategy to allow patients to get optimized RAASi therapy while simultaneously lowering the risk of hyperkalemia.”
To date, Veltassa is the only potassium binder studied in placebo-controlled trials proven to control potassium without compromising RAASi in a variety of patient profiles.
Vifor Pharma continues to support several real world data generation programs with the ongoing phase-IV PLATINUM study and the CARE-HK in HF global registry to evaluate evidence-based care using Veltassa® in chronic kidney disease and heart failure patients. First results on the baseline data and retrospective analyses from CARE-HK in HF are expected in 2022.
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency and nephrology. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions across iron, dialysis, nephrology and rare conditions. Vifor Pharma Group strives to help patients around the world with severe, chronic and rare diseases lead better, healthier lives. It specializes in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and includes the companies: Vifor Pharma, Sanifit Therapeutics, and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit viforpharma.com.
About the DIAMOND trial
This prospective phase-III multicenter, double-blind, randomized withdrawal, placebo-controlled trial was designed to evaluate the potential role of Veltassa® in enabling patients with, or at high risk of, hyperkalemia to remain on RAASi therapy. DIAMOND is the largest interventional study for potassium binders assessing control of serum potassium, hyperkalemia events, and enablement of RAASi in heart failure patients with reduced ejection fraction and hyperkalemia in more than 1,000 patients. On recommendation of the independent study Executive Committee and due to COVID-19 impact on recruitment, the primary endpoint has been changed in June 2021 to investigate the role of Veltassa® in controlling serum potassium, preventing hyperkalemia and maintain RAASi use in heart failure patients.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220403005054/en/
Contact information
Contact and further information:
Nathalie Ponnier
Global Head Corporate Communications
+41 79 957 96 73
media@viforpharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
Fitch Learning Completes Acquisition of Moody’s Analytics Learning Solutions and the Canadian Securities Institute5.12.2025 17:48:00 EET | Press release
Fitch Learning, the global leader in financial learning and professional certifications, today announced the completion of its acquisition of Moody’s Analytics Learning Solutions (MALS) and the Canadian Securities Institute (CSI). MALS is a global provider of credit and digital learning, and CSI is a leading provider of certifications for the Canadian financial services industry. Fitch Learning, recognized globally as the premier financial education provider, delivers specialized training for the financial services industry through accredited qualifications, flexible corporate solutions programs, managed services and digital learning solutions trusted by leading institutions worldwide. The combined business will serve over 92,000 finance professionals across 148 countries, at every stage of their careers. “This acquisition is about creating more opportunities for growth – for organizations and for individuals,” said Andreas Karaiskos, CEO of Fitch Learning. “By combining both organizat
Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation5.12.2025 17:00:00 EET | Press release
Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design, develop, and operate a portfolio of digital and AI solutions aimed at improving efficiency and automating complex business processes. The launch of this new company is the direct outcome of a year of successful collaboration between the two firms and marks a new phase in their shared ambition to bring scalable, high-performance digital solutions to market, aiming to further augment their clients’ capacity to compress time to impact in a variety of domains. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205465303/en/ Arthur D. Little and Vega IT have announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design, develop, and operate a portfolio of digital and AI solutions. Axceler8 Solutions’ first product, Axceler8 Rx, is now live as a newly developed platform, and is a
Lone Star Announces Sale of SPX FLOW to ITT Inc.5.12.2025 14:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell SPX FLOW, Inc. (“SPX FLOW”), a leading provider of highly engineered equipment and process technologies for attractive end markets including industrial, health and nutrition, to ITT Inc. (NYSE: ITT) for $4.775 billion in cash and shares of common stock. Based in Charlotte, N.C., SPX FLOW focuses on process technologies delivering mixing, blending, fluid handling, separation, thermal heat transfer and other solutions integral to industrial, health and nutrition markets. The company has operations in more than 25 countries and sales in more than 140 countries. In partnership with Lone Star, SPX FLOW has focused on improving its sales execution and operating platform, while ensuring high quality and innovative product development. The management team has improved the company’s commercial organization and executed growth initiatives to build its presence in e
AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGA Company Named ANV Group Holdings Ltd.5.12.2025 14:00:00 EET | Press release
AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV Specialty, Risico, Collegiate, ANV Nordic, Arc Legal, Qualis, and Abacus. These businesses provide diverse risk and insurance coverages including cyber excess and surplus (E&S), directors and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom